KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma

Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab

Renal cell cancer: Highlights from ASCO 2020

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma

CAPIRI versus irinotecan for the treatment of advanced gall bladder cancer patients progressing on first-line chemotherapy

DELIVER: Investigating the efficacy of nivolumab treatment in gastric cancer

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogenetic risk

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study